胃癌HER-2表达的临床意义及血管新生相关性研究

doi:10.11904/j.issn.1002-3070.2015.05.012

摘要/Abstract

摘要： 目的本研究通过检测人表皮生长因子受体-2(HER-2)在胃癌及癌旁组织中的表达,分析其与临床病理特征、血管生成以及术后早期复发的关系,旨在探讨胃癌中HER-2表达的临床意义,为胃癌患者术后制定有效的治疗方案提供理论和临床基础。方法回顾性分析我科室2012年3月—2013年7月行手术切除的原发胃癌组织398例及相应的癌旁正常组织363例,应用免疫组织化学(Immunohistochemistry,IHC)结合荧光原位杂交(Fluorescence in situ hybridization,FISH)检测肿瘤组织及癌旁正常组织HER-2阳性表达率,同时分析HER-2表达与临床病理特征、血管生成以及术后早期复发的关系。结果 (1)胃癌组织中HER-2的阳性表达率为14.07%(56/398),显著高于癌旁非肿瘤组织0(0/363)(P＜0.05);(2)Lauren分型、肿瘤部位、脉管浸润情况、TNM分期、有无淋巴结转移与HER-2阳性表达相关(P＜0.05),而年龄、性别、肿瘤大小、分化程度、生长方式与HER-2表达无相关性(P＞0.05)。T分期中,T₄期的HER-2表达率高于(T₁+T₂+T₃)期,但无统计学差异(P＞0.05);(3)56例HER-2阳性表达组的微血管密度(Microvessel density,MVD)值为58.63±19.97,342例HER-2阴性表达组的MVD值为49.04±19.25,具有统计学差异,经Spearman等级相关性分析,两组间呈正相关(r=4.33,P＜0.001);(4)早期复发率方面,HER-2阳性表达组1年、1.5年复发率分别为16.00%、38.00%,高于HER-2阴性表达组的8.81%、25.53%,但无统计学差异(P＞0.05)。结论 HER-2在胃癌组织中存在着过度表达,HER-2的过度表达与胃癌患者的Lauren分型、肿瘤部位、脉管浸润情况、TNM分期、有无淋巴结转移具有相关性,而与年龄、性别、肿瘤大小、分化程度、生长方式无关;HER-2的过度表达与肿瘤新生血管生成呈正相关;HER-2的过度表达与术后的早期复发可能存在相关性,需待进一步的随访观察。

关键词: 胃癌, 免疫组化, 人表皮生长因子受体-2, 微血管密度, 复发率

Abstract: Objective The purpose of this study is to investigate the expression of human epidermal growth factor receptor-2(HER-2)in gastric carcinoma tissue and normal gastric tissue of these patients,and its relationship with the clinical pathological characteristic,the microvessel density(MVD)and early post-operative recurrence,and to analyze the clinical significance of expression of HER-2 in gastric carcinoma,in order to lay the theoretical foundation of effective therapy for gastric carcinoma.Methods The clinical data of 398 cases of gastric cancer and 363 cases of their adjacent non tumorous gastric tissue of Liaoning Cancer Hospital from March 2012 to July 2013 were analyzed retrospectively.The expression of HER-2 gene was detected by IHC method and Fish method.The expressive rate of HER-2 in gastric carcinoma tissue and normal gastric tissue of these patients were compared,and its relationship with the clinical pathological characteristic,MVD and early post operative recurrence were also analyzed.Results (1)Expressive rate of HER-2 in 398 cases of gastric cancer tissue was 14.07%(56/398),which was higher than that in all the adjacent non tumorous gastric tissue presented none expression 0(0/363)(P＜0.05);(2)In gastric cancer tissue of 398,the expression of HER-2 was related with Lauren type,tumor site,vessel invasion status,TNM stage,lymph node metastases(P＜0.05),and it had no correlation with age,sex,tumor size,histological differentiation degree,growth patterns of cancer(P＞0.05).Expressive rate of HER-2 in T4 stage was higher than(T₁+T₂+T₃)stage,but the difference was not statistically significant(P＞0.05).(3)The value of MVD in HER-2 expressive group(58.63±19.97)was significantly higher than those in HER-2 non expressive group(49.04±19.25).A positive significant correlation was found between HER-2 and MVD expression using the rank correlation matrix(P＜0.001,r=4.33).(4)1 year and 1.5 year of early post operative recurrence rate in HER-2 expressive group were 16.00%、38.00%,in HER-2 non expressive group were 8.81%,25.53%,the difference was not statistically significant(P＞0.05).Conclusion There is excessive expression of HER-2 in gastric cancer tissue,excessive expression of HER-2 patients with gastric cancer is correlated with Lauren type,tumor location,vessel invasion status,TNM stage,lymph node metastases;it displays no correlation with age,sex,tumor size,histological differentiation degree,growth patterns of cancer.HER-2 expression is positively associated with MVD value.Excessive expression of HER-2 is possible to be correlative with early post operative recurrence,and it must have further follow up to confirm.

Key words: Gastric cancer, Immunohistochemical, Human epidermal growth factor receptor-2, Microvessel density, Neoplasm recurrence rate

中图分类号:

R735.2

郑国良, 郑志超, 赵岩, 张涛, 张剑军. 胃癌HER-2表达的临床意义及血管新生相关性研究[J]. 实用肿瘤学杂志, 2015, 29(5): 438-443.

ZHENG Guoliang, ZHENG Zhichao, ZHAO Yan, ZHANG Tao, ZHANG Jianjun. Clinical significance and correlation with angiogenesis of human eqidermal growth factor receptor-2 in gastric carcinoma[J]. PRACTICAL ONCOLOGY JOURNAL, 2015, 29(5): 438-443.

参考文献

1 Ferlay J,Soerjomataram I,Dikshit R,et al.Cancer incidence and mortality worldwide:sources,methods and major patterns in GLOBOCAN 2012[J].Int J Cancer,2015,136(5):359-386.
2 Ferro A,Peleteiro B,Malvezzi M,et al.Worldwide trends in gastric cancer mortality(1980-2011),with predictions to 2015,and incidence by subtype[J].Eur J Cancer,2014,50(7):1330-1344.
3 Kumar R,Yarmand-Bagheri R.The role of HER2 in angiogenesis[J].Semin Oncol,2001,28(5 Suppl 16):27-32.
4 Buttitta F,Barassi F,Fresu G,et al.Mutational analysis of the HER2 gene in lung tumors from Caucasian patients:mutations are mainly present in adenocarcinomas with bronchioloalveolar features[J].Int J Cancer,2006,119(11):2586-2591.
5 Bang YJ,Van Cutsem E,Feyereislova A,et al.Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer(ToGA):a phase 3,open-label,randomised controlled trial[J].Lancet,2010,376(9742):687-697.
6 Hofmann M,Stoss O,Shi D,et al.Assessment of a HER2 scoring system for gastric cancer:results from a validation study[J].Histopathology,2008,52(7):797-805.
7 Grabsch H,Sivakumar S,Gray S,et al.HER2 expression in gastric cancer:Rare,heterogeneous and of no prognostic value-conclusions from 924 cases of two independent series[J].Cell Oncol,2010,32(1-2):57-65.
8 Lee KE,Lee HJ,Kim YH,et al.Prognostic significance of p53,nm23,PCNA and c-erbB-2 in gastric cancer[J].Jpn J Clin Oncol,2003,33(4):173-179.
9 Zhou Y,Ran J,Tang C,et al.Effect of celecoxib on E-cadherin,VEGF,Microvessel density and apoptosis in gastric cancer[J].Cancer Biol Ther,2007,6(2):269-275.
10 Vogl G,Bartel H,Dietze O,et al.HER2 is unlikely to be involved in directly regulating angiogenesis in human breast cancer[J].Appl Immunohistochem Mol Morphol,2006,14(2):138-145.
11 Alameddine RS,Otrock ZK,Awada A,et al.Crosstalk between HER2 signaling and angiogenesis in breast cancer:molecular basis,clinical applications and challenges[J].Curr Opin Oncol,2013,25(3):313-324.
12 Weidner N.Current pathologic methods for measuring intratumoral microvessel density within breast carcinoma and other solid tumors[J].Breast Cancer Res Treat,1995,36(2):169-180.
13 Hofmann M,Stoss O,Shi D,et al.Assessment of a HER2 scoring system for gastric cancer:results from a validation study[J].Histopathology,2008,52(7):797-805.
14 李森,李治国,成龙,等.Her-2阳性胃癌靶向治疗的研究进展[J].实用肿瘤学杂志,2015,29(2):188-192.
15 公维鹏,郭洪亮,赵红伟,等.胃癌组织HER-2表达与临床病理因素相关性的探讨[J].中华肿瘤防治杂志,2010,20(7):510-512.
16 Smolej L,Kasparova P.Choice of endothelial marker is crucial for assessment of bone marrow microvessel density in chronic lymphocytic leukemia[J].APMIS,2008,116(12):1058-1062.
17 Erdem O,Dursun A,Coskun U,et al.The prognostic value of p53 and c-erbB-2 expression,proliferative activity and angiogenesis in node-negative breast carcinoma[J].Tumori,2005,91(1):46-52.
18 Park DI,Yun JW,Park JH,et al.HER-2/neu amplification is an independent prognostic factor in gastric cancer[J].Dig Dis Sci,2006,51(8):1371-1379.

[1]	秦文,赵楠楠,韩永焕,徐亚君. ZNF436在胃癌中的表达及调控WNT/β-catenin对胃癌细胞迁移及侵袭的影响[J]. 实用肿瘤学杂志, 2019, 33(3): 222-227.
[2]	孟海,杜观祥,朱利玲,汤琪云. WEE1在胃癌组织中的表达及对患者预后的影响[J]. 实用肿瘤学杂志, 2019, 33(3): 239-243.
[3]	刘佳音,燕飞虎,张艳桥. 凋亡基因Caspase3和Caspase7单核苷酸多态性与胃癌遗传易感性研究[J]. 实用肿瘤学杂志, 2019, 33(3): 250-255.
[4]	白玉贤, 马仲娟, 苏颖玲, 慕安国, 谢蕊. 胃癌患者FHIT、hMLH1、p16、RAR-beta、Reprimo和TIMP3基因的甲基化研究[J]. 实用肿瘤学杂志, 2019, 33(1): 8-13.
[5]	张凤春, 江莺, 刘照南, 闫宁宁, 崔洪全, 徐迎春. 系统性炎症相关指标中性粒细胞/淋巴细胞比值及血小板/淋巴细胞比值在根治性切除术后的胃癌患者的预后意义[J]. 实用肿瘤学杂志, 2019, 33(1): 34-39.
[6]	张宝综述, 郑志超校审. 进展期胃癌淋巴结清扫研究进展[J]. 实用肿瘤学杂志, 2019, 33(1): 78-81.
[7]	唐淑丽, 何匡邦, 张纯慧, 程佳楠, 张艳桥. 胃癌组织中miR-320a和CYLD的表达及与临床病理特征及预后的关系[J]. 实用肿瘤学杂志, 2018, 32(6): 538-544.
[8]	伊庆亭, 张红军, 姜韬, 傅佳雷, 华明涛. 多烯磷脂酰胆碱在裸鼠模型中逆转胃癌细胞奥沙利铂耐药的作用及机制研究[J]. 实用肿瘤学杂志, 2018, 32(5): 385-390.
[9]	闫石, 霍明鸣, 庞慧, 李焱, 蔡莉. p53对绝经后HR阳性、HER-2阳性术后乳腺癌患者内分泌药物疗效的预测价值[J]. 实用肿瘤学杂志, 2018, 32(3): 234-213.
[10]	姚强, 王宽, 薛英威. SRC1在胃癌中的表达及其与预后的关系[J]. 实用肿瘤学杂志, 2018, 32(2): 97-102.
[11]	余嘉惠, 刘煊, 李琦, 陆烨, 岳小强. 长链非编码RNA在胃癌中的调控机制及中药对其作用的研究概况[J]. 实用肿瘤学杂志, 2018, 32(1): 47-52.
[12]	刘国慧, 谷安鑫, 殷洪涛, 曹阳, 贺云龙, 王春波, 鄂明艳. 原苏木素A对胃癌SGC-7901细胞系放疗增敏作用的研究[J]. 实用肿瘤学杂志, 2017, 31(6): 500-505.
[13]	张纯慧, 刘霞, 徐京京, 周艳华, 赵娟, 李志伟, 张艳桥. 633例胃癌患者临床病理特征及生存分析[J]. 实用肿瘤学杂志, 2017, 31(5): 396-404.
[14]	张云艳, 刘亚琴, 王磊, 张琳, 成海燕, 杨姗姗. RIZ1蛋白表达与宫颈鳞状细胞癌临床病理参数及放疗敏感性的相关性研究[J]. 实用肿瘤学杂志, 2017, 31(5): 405-410.
[15]	孙丽娜, 赵晓迪综述, 卢瑗瑗, 王新审校. LncRNA与胃肠道肿瘤化疗耐药的研究进展[J]. 实用肿瘤学杂志, 2017, 31(5): 448-453.